XML 25 R14.htm IDEA: XBRL DOCUMENT v3.25.3
EARNINGS PER SHARE
 6 Months Ended
Sep. 27, 2025
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
7. EARNINGS PER SHARE
The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations:
 Three Months EndedSix Months Ended
September 27, 2025September 28, 2024September 27, 2025September 28, 2024
(Dollars and Shares in Thousands, Except Per Share Data)
Net income$38,684 $33,831 $72,715 $72,204 
Basic weighted average shares outstanding47,590 50,898 47,850 50,920 
Dilutive net effect of common stock equivalents74 342 159 482 
Diluted weighted average shares47,664 51,240 48,009 51,402 
Net income per share
Basic$0.81 $0.66 $1.52 $1.42 
Diluted$0.81 $0.66 $1.51 $1.40 
Anti-dilutive shares excluded from the calculation1,134 795 1,041 765 
Basic earnings per share is calculated using the Company’s weighted average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company’s common shares has been less than the applicable initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion values of both the convertible senior notes.
2022 Share Repurchase Program
In August 2022, the Board approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.
In April 2025, the Company completed a $150.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Goldman Sachs & Co. in February 2025. The total number of shares repurchased under the ASR was 2,386,131 at an average price per share upon final settlement of $62.86. As of March 29, 2025, the Company had fully funded the $300.0 million authorization under the 2022 share repurchase program.
2025 Share Repurchase Program
In April 2025, the Board approved a new three-year share repurchase program authorizing the repurchase of up to $500.0 million of Haemonetics common stock, based on market conditions, through April 2028. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. In addition to this share repurchase activity, the Company’s capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate its long-term growth plans. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.
In August 2025, the Company entered into an ASR with Citibank N.A. (“Citibank”) to repurchase $75.0 million of the Company’s common stock. Pursuant to the terms of the ASR, in August 2025, the Company paid Citibank $75.0 million in cash and received an initial delivery of 1,113,586 shares of the Company's common stock representing 80% of the notional amount of the ASR. The ASR was completed in September 2025 within the second quarter of fiscal 2026, and 316,993 additional shares were delivered upon settlement. The total number of shares repurchased under the ASR was 1,430,579 at an average price per share upon final settlement of $52.43. As of September 27, 2025, the total remaining authorization for repurchases of the Company's common stock under the 2025 share repurchase program was $425.0 million.